European Commission. Regulation (EC) No 141/2000 of the European Parliament and the Council of 16 December 1999 on orphan medicinal products. Official Journal of the European Communities 2000; L 18/1 [online]. Available from URL: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2000:018:0001:0005:en:PDF [Accessed 2012 Jun 21]
United States Congress. The Orphan Drug Act. CFR Title 21 Part 316 Orphan Drugs. United States Congress 1983 [online]. Available from URL: http://law.justia.com/cfr/title21/21-5.0.1.1.6.html [Accessed 2011 Apr 4]
Denis A, Mergaert L, Fostier C, et al. A comparative study of European rare disease and orphan drug markets. Health Pol 2010; 97: 173–9 Article Google Scholar
Picavet E, Dooms M, Cassiman D, et al. Orphan drugs for rare diseases: grounds for special status. Drug Dev Res. In press
Tambuyzer E. Rare diseases, orphan drugs and their regulation: questions and misconceptions. Nat Rev Drug Discov 2010 Dec; 9(12): 921–9 ArticlePubMedCAS Google Scholar
McCabe C, Stafinski T, Menon D. Is it time to revisit orphan drug policies?. Yes, for equity’s sake. BMJ 2010; 341: c4777 ArticlePubMed Google Scholar
Burls A, Austin D, Moore D. Commissioning for rare diseases: view from the frontline. BMJ 2005 Oct 29; 331(7523): 1019–21 ArticlePubMed Google Scholar
Desser AS, Gyrd-Hansen D, Olsen JA, et al. Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67. BMJ 2010; 341: c4715 ArticlePubMed Google Scholar
Nord E. The trade-off between severity of illness and treatment effect in cost-value analysis of health care. Health Policy 1993 Aug; 24(3): 227–38 ArticlePubMedCAS Google Scholar
Ubel PA, Loewenstein G. Distributing scarce livers: the moral reasoning of the general public. Soc Sci Med 1996 Apr; 42(7): 1049–55 ArticlePubMedCAS Google Scholar
McCabe Tsuchiya A, Claxton K, et al. Orphan drugs revisited. QJM 2006 May; 99(5): 341–5 Article Google Scholar
Cookson R, McCabe C, Tsuchiya A. Public healthcare resource allocation and the rule of rescue. J Med Ethics 2008; 34(7): 540–4 ArticlePubMedCAS Google Scholar
Jonsen AR. Bentham in a box: technology assessment and health care allocation. Law Med Health Care 1986; 14(3–4): 172–4 PubMedCAS Google Scholar
McCabe C. Balancing economic, ethical and equity concerns in orphan drugs and rare diseases. Eur J Hosp Pharm Practice 2010; 16(4): 22–4 Google Scholar
Denis A, Mergaert L, Fostier C, et al. Issues surrounding orphan disease and orphan drug policies in Europe. Appl Health Econ Health Policy 2010; 8(5): 343–50 ArticlePubMed Google Scholar
Heemstra HE. Variations in access and use of orphan drugs among EU Member States. Eur J Hosp Pharm Practice 2010; 16(4): 25–7 Google Scholar
Barton JH, Emanuel EJ. The patents-based pharmaceutical development process: rationale, problems, and potential reforms. JAMA 2005 Oct 26; 294(16): 2075–82 ArticlePubMedCAS Google Scholar
Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis 2011 Jun 17; 6: 42 ArticlePubMed Google Scholar
Picavet E, Dooms M, Cassiman D, et al. Drugs for rare diseases: orphan designation status influences price. Appl Health Econ Health Policy 2011; 9(4): 1–5 Article Google Scholar
Hollis A. Drugs for rare diseases: paying for innovation. In: Beach C, editor. Health services restructuring in Canada: new evidence and new directions. Montreal (QC): McGill-Queen’s University Press, 2006 Google Scholar
Loughnot D. Potential interactions of the Orphan Drug Act and pharmacogenomics: a flood of orphan drugs and abuses?. Am J Law Med 2005; 31(2–3): 365–80 PubMed Google Scholar
Gatta G, van der Zwan JM, Casali PG, the RARECARE working group. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer 2011; 47: 2493–511 ArticlePubMed Google Scholar
DiMasi JA, Grabowski HG. Economics of new oncology drug development. J Clin Oncol 2007; 25(2): 209–16 ArticlePubMed Google Scholar
Drummond MF, Wilson DA, Kanavos P, et al. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care 2007; 23(1): 36–42 ArticlePubMed Google Scholar
Grabowski HG, Vernon J. The distribution of sales revenues from pharmaceutical innovation. Pharmacoeconomics 2000; 18 Suppl. 1: 21–32 ArticlePubMed Google Scholar
Wellman-Labadie O, Zhou Y. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?. Health Policy 2009 Dec 24; 95(2–3): 216–28 PubMed Google Scholar
Ekins S, Williams AJ, Krasowski MD, et al. In silico repositioning of approved drugs for rare and neglected diseases. Drug Discov Today 2011 Apr; 16(7–8): 298–310 ArticlePubMed Google Scholar
Maurer SM. Choosing the right incentive strategy for research and development in neglected diseases. Bull World Health Organ 2006 May; 84(5): 376–81 ArticlePubMed Google Scholar
McCabe C, Edlin R, Round J. Economic considerations in the provision of treatments for rare diseases. Adv Exp Med Biol 2010; 686: 211–22 ArticlePubMed Google Scholar
Posada de la Paz M, Groft SC, editors. Rare diseases epidemiology. Advances in Experimental Medicine and Biology — Vol. 686. Dordrecht: Springer Science+Business Media, 2010 Google Scholar
Drummond M, Evans B, LeLorier J, et al. Evidence and values: requirements for public reimbursement of drugs for rare diseases: a case study in oncology. Can J Clin Pharmacol 2009; 16(2): e273–81 PubMed Google Scholar
Claxton KP, Sculpher MJ. Using value of information analysis to prioritise health research: some lessons from recent UK experience. Pharmacoeconomics 2006; 24(11): 1055–68 ArticlePubMed Google Scholar
Tunis SR, Pearson SD. Coverage options for promising technologies: Medicare’s ‘coverage with evidence development’. Health Aff (Millwood) 2006 Sep; 25(5): 1218–30 Article Google Scholar
Stafinski T, McCabe CJ, Menon D. Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems. Pharmacoeconomics 2010; 28(2): 113–42 ArticlePubMed Google Scholar
Owen A, Sprinks J, Meehan A, et al. A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian Pharmaceutical Benefits Scheme: the Bosentan Patient Registry. J Med Econ 2008; 11: 235–43 PubMed Google Scholar
Cook JP, Vernon JA, Manning R. Pharmaceutical risk-sharing agreements. Pharmacoeconomics 2008; 26(7): 551–6 ArticlePubMed Google Scholar
Connock M, Juarez-Garcia A, Frew E. A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry’s disease and mucopolysaccharidosis type 1. Health Technol Assess 2006; 10(20): iii–113 Google Scholar
McCabe C, Claxton K, Tsuchiya A. Orphan drugs and the NHS: should we value rarity? BMJ 2005 Oct 29; 331(7523): 1016–9 ArticlePubMed Google Scholar